5-[4-(4-methylpiperazin-1-yl)benzamido]-2-(quinolin-8-ylamino)thiazole-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-[4-(4-methylpiperazin-1-yl)benzamido]-2-(quinolin-8-ylamino)thiazole-4-carboxamide
• 英文别名: 5-[[4-(4-Methylpiperazin-1-yl)benzoyl]amino]-2-(quinolin-8-ylamino)-1,3-thiazole-4-carboxamide；5-[[4-(4-methylpiperazin-1-yl)benzoyl]amino]-2-(quinolin-8-ylamino)-1,3-thiazole-4-carboxamide
• 化学式: C₂₅H₂₅N₇O₂S
• 分子量: 487.585
• InChiKey: FZELPUUWRFBLBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• NOVEL BICYCLIC THIAZOLE COMPOUNDS
  申请人：CARNA BIOSCIENCES, INC.

  公开号：US20150133656A1

  公开（公告）日：2015-05-14

  The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R 1 , R 2 , R 3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型双环噻唑化合物，其抑制TRAF2和Nck相互作用激酶（TNIK），因此可用作TNIK抑制剂，用于治疗癌症患者，特别是实体瘤癌症患者，如结直肠癌、胰腺癌、非小细胞肺癌、前列腺癌或乳腺癌。所述双环噻唑化合物由下式（I）表示（其中R1、R2、R3和Q如规范中所定义），或其药学上可接受的盐。
• US9102637B2
  申请人：——

  公开号：US9102637B2

  公开（公告）日：2015-08-11
• [EN] NOVEL BICYCLIC THIAZOLE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THIAZOLES BICYCLIQUES
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2013176293A1

  公开（公告）日：2013-11-28

  The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.